Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: Hong Kong
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Generic Pharma

Sihuan Pharmaceutical Holdings Group Ltd

+ Add to Watchlist

460:HK

4.410 HKD 0.0000.00%

As of 04:01:04 ET on 03/31/2015.

Trading has been suspended for 460:HK

Snapshot for Sihuan Pharmaceutical Holdings Group Ltd (460)

Open: 4.410 Day's Range: 4.410 - 4.410 Volume: 0
Previous Close: 4.410 52wk Range: 4.085 - 6.680 1-Yr Rtn: -5.15%

Stock Chart for 460

No chart data available.
  • 460:HK 4.410
  • 1D
  • 1M
  • 1Y
4.410
Interactive 460 Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for 460

Current P/E Ratio (ttm) 24.0937
Estimated P/E(12/2014) 21.1129
Relative P/E vs. HSI 2.2962
Earnings Per Share (CNY) (ttm) 0.1463
Est. EPS (CNY) (12/2014) 0.1670
Est. PEG Ratio 0.9023
Market Cap (M HKD) 45,706.04
Shares Outstanding (M) 10,364.18
30 Day Average Volume 27,327,040
Price/Book (mrq) 4.2372
Price/Sale (ttm) 8.2829
Dividend Indicated Gross Yield 0.67%
Cash Dividend (CNY) 0.0130
Dividend Ex-Date 09/10/2014
5 Year Dividend Growth -
Next Earnings Announcement 03/31/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for 460

  • Revenue
  • Net Income (M/CNY)
  • Profit Margin (%)

Company Profile & Key Executives for 460

Sihuan Pharmaceutical Holdings Group Ltd. researches and develops cardiocerebral vascular drugs in China. The Company drugs address needs in the areas of anti-infective, metabolism, cardiovascular system, oncology and nervous system.

Che FengshengChairman/Exec Dir/Co-FounderGuo WeichengDpty Chairman/CEO/Executive Director
Choi Yiau ChongCFO/Joint SecretaryJia ZhongxinChief Operating Officer
More Company Profile & Key Executives for 460

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil